Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up.

Montalescot G, Antoniucci D, Kastrati A, Neumann FJ, Borentain M, Migliorini A, Boutron C, Collet JP, Vicaut E.

Eur Heart J. 2007 Feb;28(4):443-9. Epub 2007 Jan 24.

PMID:
17251257
2.

Optimizing the use of abciximab and intracoronary stents in patients with acute ST elevation myocardial infarction.

Velianou JL, Al-Suwaidi J, Mathew V.

Am J Cardiovasc Drugs. 2002;2(5):315-22. Review.

PMID:
14727961
3.

Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials.

Kandzari DE, Hasselblad V, Tcheng JE, Stone GW, Califf RM, Kastrati A, Neumann FJ, Brener SJ, Montalescot G, Kong DF, Harrington RA.

Am Heart J. 2004 Mar;147(3):457-62. Review.

PMID:
14999194
4.

Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.

Ibbotson T, McGavin JK, Goa KL.

Am J Cardiovasc Drugs. 2003;3(5):381-6. Review.

PMID:
14728074
6.

Coronary stenting and abciximab in primary angioplasty for ST-segment-elevation myocardial infarction.

De Luca G, Suryapranata H, Grimaldi R, Chiariello M.

QJM. 2005 Sep;98(9):633-41. Epub 2005 Jul 22. Review.

PMID:
16040669
7.

Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials.

De Luca G, Verdoia M, Suryapranata H.

Atherosclerosis. 2012 Jun;222(2):426-33. doi: 10.1016/j.atherosclerosis.2012.02.041. Epub 2012 Mar 7. Review.

PMID:
22483166
8.

Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials.

Kubica J, Koziński M, Navarese EP, Tantry US, Grześk G, Fabiszak T, Kubica A, Świątkiewicz I, Bliden KP, Gurbel PA.

Cardiol J. 2012;19(3):230-42. Review.

10.

Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab.

Diaz JF, Cardenal R, Gomez-Manchero A, Sanchez-Gonzalez C.

Cardiovasc Hematol Agents Med Chem. 2011 Jul 1;9(3):147-53. Review.

PMID:
21718242
11.
13.

Stenting and abciximab in primary angioplasty: a review of current status.

De Luca G, Suryapranata H, Piscione F, Barbato E, Chiariello M.

Ital Heart J. 2005 Nov;6(11):874-80. Review.

PMID:
16320920
14.

Abciximab. An updated review of its use in ischaemic heart disease.

Foster RH, Wiseman LR.

Drugs. 1998 Oct;56(4):629-65. Review. Erratum in: Drugs 1999 Jan;57(1):91.

PMID:
9806109
15.

Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials.

Valgimigli M, Biondi-Zoccai G, Tebaldi M, van't Hof AW, Campo G, Hamm C, ten Berg J, Bolognese L, Saia F, Danzi GB, Briguori C, Okmen E, King SB, Moliterno DJ, Topol EJ.

Eur Heart J. 2010 Jan;31(1):35-49. doi: 10.1093/eurheartj/ehp376. Epub 2009 Sep 14. Review.

PMID:
19755402
16.

Intracoronary versus intravenous abciximab administration in STEMI patients: overview of current status and open questions.

Kubica A, Kozinski M, Navarese EP, Grzesk G, Goch A, Kubica J.

Curr Med Res Opin. 2011 Nov;27(11):2133-44. doi: 10.1185/03007995.2011.621417. Epub 2011 Sep 26. Review.

PMID:
21942506
17.

Primary percutaneous coronary intervention for acute MI: improving access and outcomes.

Karha J, Hook MA, Brener SJ.

Cleve Clin J Med. 2005 Jul;72(7):559-60, 562, 565-6 passim. Review.

PMID:
16044653
18.
19.

[Abciximab in the treatment of acute coronary syndromes by angioplasty and stents].

Pinton P.

Therapie. 1998 Jul-Aug;53(4):341-7. Review. French.

PMID:
9806003
20.

Acute ST-elevation myocardial infarction.

Bates ER, Menees DS.

Curr Opin Crit Care. 2012 Oct;18(5):417-23. doi: 10.1097/MCC.0b013e328357f07b. Review.

PMID:
22889871

Supplemental Content

Support Center